...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Evidence-based medications for the treatment of the inflammatory bowel diseases.
【24h】

Evidence-based medications for the treatment of the inflammatory bowel diseases.

机译：用于治疗炎症性肠病的循证药物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Evidence-based medicine is an increasingly important tool to aid the clinician in the treatment of patients. This is particularly true for diseases such as the inflammatory bowel diseases, for which the pathogenesis is unknown and an extensive range of treatment options is available. High quality data may not be available for all decisions, but it is essential that clinicians are aware of well-grounded data that are available. RECENT FINDINGS: The body of data supporting the use of biological therapies in inflammatory bowel disease continues to grow and diversify. Regulatory requirements and academic expectations are evolutionary forces that are resulting in continuous improvement in the quality of studies. SUMMARY: This review will update the reader on several significant analyses that have been published recently. It is intended to raise awareness of the data, helping clinicians to evaluate new treatments and to revisit older treatments with a critical eye.
机译：审查目的：循证医学是一种越来越重要的工具，可以帮助临床医生治疗患者。对于诸如炎症性肠病的疾病尤其未知，其发病机理是未知的，并且可获得广泛的治疗选择。高质量的数据可能并不适用于所有决策，但至关重要的是，临床医生必须了解可以充分利用的基础数据。最近的发现：支持在炎症性肠病中使用生物疗法的数据不断增长和多样化。监管要求和学术期望是不断发展的力量，可以不断提高研究质量。摘要：这篇评论将使读者了解最近发表的一些重要分析。旨在提高对数据的认识，帮助临床医生评估新疗法并用敏锐的眼光重新审视旧疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号